The federal government has invested $15.97 million in a project designed to establish a fully domestic pharmaceutical supply chain in Virginia.
The investment from the U.S. Economic Development Administration will support the Alliance for Building Better Medicine’s End-to-End Commercialization Project. The effort will focus on four essential sterile injectable medicines: ketamine, midazolam, norepinephrine and succinylcholine. Finished medicines will be produced at a Virginia plant.
More than 130 million Americans rely on medicines produced through global manufacturing networks. The project is intended to strengthen domestic drug production and supply chains.
The alliance’s project is led by nonprofit drugmaker Civica. CEO Ned McCoy told Becker’s earlier this year that the company’s Petersburg, Va., plant — the same facility central to this project — was on track to launch its first medication in early 2026, part of a yearslong effort to reduce reliance on Chinese-sourced pharmaceutical ingredients.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
